Myocet delivers doxorubicin directly to the cancer cells while minimizing exposure to healthy tissues. The liposomal formulation encapsulates the drug, allowing it to circulate in the bloodstream longer and preferentially target tumor tissues. This targeted delivery helps to reduce side effects, particularly those affecting the heart.
